- Research article
- Open Access
Serum repressing efflux pump CDR1 in Candida albicans
© Yang et al; licensee BioMed Central Ltd. 2006
- Received: 23 February 2006
- Accepted: 13 July 2006
- Published: 13 July 2006
In the past decades, the prevalence of candidemia has increased significantly and drug resistance has also become a pressing problem. Overexpression of CDR1, an efflux pump, has been proposed as a major mechanism contributing to the drug resistance in Candida albicans. It has been demonstrated that biological fluids such as human serum can have profound effects on antifungal pharmacodynamics. The aim of this study is to understand the effects of serum in drug susceptibility via monitoring the activity of CDR1 promoter of C. albicans.
The wild-type C. albicans cells (SC5314) but not the cdr1/cdr1 mutant cells became more susceptible to the antifungal drug when the medium contained serum. To understand the regulation of CDR1 in the presence of serum, we have constructed CDR1 promoter-Renilla luciferase (CDR1p-RLUC) reporter to monitor the activity of the CDR1 promoter in C. albicans. As expected, the expression of CDR1p-RLUC was induced by miconazole. Surprisingly, it was repressed by serum. Consistently, the level of CDR1 mRNA was also reduced in the presence of serum but not N-acetyl-D-glucosamine, a known inducer for germ tube formation.
Our finding that the expression of CDR1 is repressed by serum raises the question as to how does CDR1 contribute to the drug resistance in C. albicans causing candidemia. This also suggests that it is important to re-assess the prediction of in vivo therapeutic outcome of candidemia based on the results of standard in vitro antifungal susceptibility testing, conducted in the absence of serum.
- Minimum Inhibitory Concentration
- Mutant Cell
- Antifungal Drug
- Drug Susceptibility
In the past decades, the prevalence of candidemia has increased significantly. Among them, Candida albicans is the most frequently isolated fungal pathogen in humans and has caused morbidity in seriously debilitated and immunocompromised hosts. Coinciding with the increased usage of antifungal drugs, the incidences of drug resistance have also increased [1, 2].
Overexpression of CDR1, an ATP binding cassette (ABC) transporter, has been shown to be the major mechanism for the drug resistance of clinical isolates . Mutations on CDR1 in C. albicans have resulted in an increased susceptibility to azole drugs , which is consistent with the observation that overexpression of CDR1 contributes to the drug resistance of clinical isolates of C. albicans . Interestingly, the expression of CDR1 is increased approximately 4-fold in Catup1/Catup1 mutant cells, which are predominately in the hyphal form . This data suggests that CaTup1 acts as a negative regulator of CDR1. Recently, two transcription factors, CaNDT80 and CaTAC1, have been identified as positive regulators of CDR1 in C. albicans [7, 8].
Previous works have demonstrated that biological fluids such as human serum can have profound effects on antifungal pharmacodynamics . During an infection, the C. albicans cells exist in the host body and are surrounded by blood and other body fluid, where they encounter the antifungal drugs. In this study, we have found that the wild-type SC5314 cells but not the cdr1/cdr1 mutant cells became more susceptible to fluconazole, a commonly used antifungal drug, when the medium contained serum. To investigate the regulation of CDR1 in the presence of serum, we have constructed a CDR1 promoter-Renilla luciferase gene (CDR1p-RLUC) reporter to monitor the activity of CDR1 promoter in C. albicans under different conditions. In conclusion, serum increases the drug susceptibility by repressing the expression of CDR1.
To determine the effect of serum on the expression of CDR1, we have measured the activities of CDR1p-RLUC in C. albicans cells that were grown in SD liquid medium in the absence or presence of 10% fetal bovine serum at 35°C for one hour. Surprisingly, the serum repressed the expression of CDR1p-RLUC. In the presence of the serum, the expression of CDR1p-RLUC was reduced to 50% of that in the absence of the serum (Fig. 3, comparing bar 1 to bar 3). To determine if human serum also has the same effect, we have also cultured the cells in the presence of 10% human serum from two healthy volunteers. Interestingly, like the fetal bovine serum, the human sera also reduced the expression of CDR1p-RLUC (Fig. 3, comparing bar 1 to bars 4 and 5).
Recently, CaNdt80 has been identified as a positive regulator of CDR1 in C. albicans . To investigate if serum represses the expression of CDR1 via CaNdt80, we have also determined the level of CDR1 in Candt80/Candt80 mutant cells. The expression of CDR1 was reduced 50% by the null mutation of CaNDT80 (Fig. 4, comparing bar 1 to bar 4), which is consistent with our previous finding that CaNdt80 regulates CDR1 positively . If regulating the expression of CDR1 by serum is independent of the activity of CaNdt80, the level of CDR1 mRNA in the Candt80/Candt80 mutant cells would be significantly reduced in the presence of serum. Otherwise, it will not (if there is any). Our data showed that although 10% fetal bovine serum further reduced the expression of CDR1 in the Candt80/Candt80 mutant cells, the effect was mild (Fig. 4, comparing bar 4 to bar 5).
We have found that the wild-type cells became more susceptible to fluconazole when the medium contained serum. Furthermore, the expression of CDR1 is repressed significantly by serum according to the activity of the reporter and CDR1 mRNA level. The level of CDR1 mRNA was only mildly reduced by serum in the Candt80/Candt80 mutant cells suggesting the major, if not the sole, regulatory ability of serum may be through the activity of CaNdt80. However, we still can not rule out the possibility that serum may also act through Tac1 and/or other unidentified regulators. It will be interesting to investigate the coordination between CaNdt80 and Tac1 in regulating the expression of CDR1 in the presence of serum.
The standard antifungal susceptibility testing , which is conducted in the absence of serum, is unreliable in predicting the clinical outcome of therapies, especially for systemic infections. Our finding may explain the existence and persistence of such a discrepancy between the susceptibilities of in vivo and in vitro environments.
Strains and media
Strains of C. albicans used in this studyare as following: SC5314, the wild-type control strain; DSY448, ura3 Δ:: λimm434/ura3 Δ:: λimm434; DSY448, ura3 Δ:: λ imm434/ura3 Δ:: λimm434 cdr1::hisG/cdr1::hisG-URA3-hisG, a gift from Dr. D. Sanglard ; YLO133, ura3 Δ:: λimm434/ura3 Δ:: λimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG Candt80::GFP-Arg4/Candt80::URA3-dpl20 ENO1/eno1::ENO1-tetR-SCHAP4-3xHA-HIS1; and YLO137, ura3 Δ:: λimm434/ura3 Δ:: λimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG Candt80::GFP-Arg4/Candt80:: URA3-dpl200:: CaNDT80::HIS1 . Yeast Peptone Dextrose (YPD) contained 1% yeast extract, 2% peptone, and 2% dextrose and Synthetic Dextrose (SD) contained 0.67% yeast nitrogen base without amino acid and 2% dextrose. All agar plates were prepared with addition of 2% agar in media.
Antifungal drug susceptibility
The minimum inhibitory concentration (MIC) to fluconazole of each strain was determined by in vitro antifungal susceptibility testing using microdilution method according to published guidelines by the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) . The antifungal agent fluconazole (Pfizer, Inc.) was freshly prepared as a stock at the concentration of 16 g/l in DMSO. For working concentration, (16~0.0312 μg/ml), it was processed by stepwise twofold dilutions in SD medium. A drug-free culture and a sterile control were included in each microtitre plate. The optical density (OD) in each well of the microtitre plate was read with a microplate reader (Molecular Devices, SPECTRA MAX plus) at 600 nm after incubated at 35°C for 48 hours. The drug inhibitory curve was presented by the OD of each well with different concentrations of fluconazole relative to the OD of the drug-free control. The MIC was defined as the lowest concentration which reduced the culture broth turbidity by 50%.
Construction of CDR1 promoter-Renilla luciferase
A 1.2 kilo-base-pair (kb) DNA fragment containing the RLUC gene modified for C. albicans with the WH11 transcription termination sequence at the 3' end of the RLUC open reading frame was isolated from pCRW3  after digested with Eco RV and Nco I. The purified DNA fragment was blunt-ended with klenow and then ligated to the pGEM-URA  at the Nae I site to construct the plasmid LOB60. Another 1.2 kb DNA fragment containing the promoter and the translation initiation site of CDR1 was generated by using oligonucleotides HJL340, 5'-d(GATCATCGATACTCAATAAG) and HJL 341, 5'-d(CGCAAGCCCGGGTAATTTTTTTC). The plasmid LOB60 was then used to construct plasmid LOB85 by introducing the PCR product at restriction sites of Cla I and Xma I (Fig. 2). The resulted LOB85 was then linearized with Eco RV at the 455 base-pair (bp) upstream of the translation initiation site of CDR1 and used for transformation to integrate into the chromosome at the promoter of CDR1 of CAI4 to produce the Ura3+ transformant, YLO185, ura3 Δ:: λimm434/ura3 Δ:: λimm434 CDR1p-RLUC-URA3 (Fig. 2).
Activity assay of CDR1 promoter-Renilla luciferase gene (CDR1p-RLUC)
Overnight pre-cultured C. albicans cells containing CDR1p-RLUC were diluted in 10 ml of the SD liquid medium to a final concentration about 4 × 106 cells per ml. Prior to the addition of serum or miconazole, the dilutents were incubated at 30°C for 4 hours. The cells were harvested after treated with 10% serum (either the fetal bovine serum provided by JRH Biosciences, Australia or the human serum from two coauthors) or 100 μg/ml of miconazole (Sigma M-3512) at 35°C for one hour. The control cells were grown in SD medium in the absence of serum and miconazole at 35°C for one hour. The cells were resuspended in lysis buffer for luciferase assay using the Dual-Glo Luciferase Assay System (E2940, Promega, Madison, USA). The activity of luciferase was determined according to the protocol provided by the manufacturer. The activity of luciferase in the control cells without treatment was defined as one and the relative activity of luciferase in cells with other treatments was normalized accordingly.
Quantitative analysis of the mRNA level by Real-Time PCR
The C. albicans cells were harvested at an OD600 between 0.7 and 0.9 after being grown in 20 ml of the SD liquid medium in the absence or presence of 10% fetal bovine serum (JRH Biosciences, Australia) or 5 mM Glu-NAc (Sigma, A8625) at 37°C for one hour. A real-time PCR was performed in a Rotor-Gene™ 3000 instrument (Corbett Research, Australia) with a TITANIUM™ Taq PCR kit (BD Clontech 639210) and SYBR®Green I Nucleic Acid Stain (Cambrex 50513) to determine the level of mRNA. The sample was automatically setup by CAS-1200™ (Corbett Research, Australia). The real-time PCR was performed according to the instructions from the manufacturer. The expression of TEF3 in each strain was used as the control. The relative quantitation was based on two standard curves for comparisons and the results were given as a ratio . The level of CDR1 mRNA isolated from the wild-type cells in the absence of serum was defined as one. The relative level of mRNA isolated from different strains was normalized accordingly.
We thank Drs. G. Fink, C. Gale, A. Mitchell, H. Nakayama, R. Prasad, and D. Sanglard for strains and plasmids. This work was in part supported by grants 94-2320-B-400-001 and 94-2320-B-009-001 from Nation Science Council and CL-094-PP-05 from National Health Research Institutes.
- Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ: Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother. 2000, 44: 747-751. 10.1128/AAC.44.3.747-751.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Yang YL, Li SY, Cheng HH, Lo HJ: Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn Microbiol Infect Dis. 2005, 51: 179-183. 10.1016/j.diagmicrobio.2004.11.004View ArticlePubMedGoogle Scholar
- Karababa M, Coste AT, Rognon B, Bille J, Sanglard D: Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob Agents Chemother. 2004, 48: 3064-3079. 10.1128/AAC.48.8.3064-3079.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Sanglard D, Ischer F, Monod M, Bille J: Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother. 1996, 40: 2300-2305.PubMed CentralPubMedGoogle Scholar
- Yang YL, Lo HJ: Mechanisms of antifungal agent resistance. J Microbiol Immunol Infect. 2001, 34: 79-86.PubMedGoogle Scholar
- Murad AM, d'Enfert C, Gaillardin C, Tournu H, Tekaia F, Talibi D, Marechal D, Marchais V, Cottin J, Brown AJ: Transcript profiling in Candida albicans reveals new cellular functions for the transcriptional repressors CaTup1, CaMig1 and CaNrg1. Mol Microbiol. 2001, 42: 981-993. 10.1046/j.1365-2958.2001.02713.xView ArticlePubMedGoogle Scholar
- Chen CG, Yang YL, Shih HI, Su CL, Lo HJ: CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1. Antimicrob Agents Chemother. 2004, 48: 4505-4512. 10.1128/AAC.48.12.4505-4512.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Coste AT, Karababa M, Ischer F, Bille J, Sanglard D: TAC 1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell. 2004, 3: 1639-1652. 10.1128/EC.3.6.1639-1652.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Zhanel GG, Saunders DG, Hoban DJ, Karlowsky JA: Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother. 2001, 45: 2018-2022. 10.1128/AAC.45.7.2018-2022.2001PubMed CentralView ArticlePubMedGoogle Scholar
- White TC, Marr KA, Bowden RA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998, 11: 382-402.PubMed CentralPubMedGoogle Scholar
- Puri N, Krishnamurthy S, Habib S, Hasnain SE, Goswami SK, Prasad R: CDR1, a multidrug resistance gene from Candida albicans, contains multiple regulatory domains in its promoter and the distal AP-1 element mediates its induction by miconazole. FEMS Microbiol Lett. 1999, 180: 213-219. 10.1111/j.1574-6968.1999.tb08798.xView ArticlePubMedGoogle Scholar
- Castilla R, Passeron S, Cantore ML: N-acetyl-D-glucosamine induces germination in Candida albicans through a mechanism sensitive to inhibitors of cAMP-dependent protein kinase. Cell Signal. 1998, 10: 713-719. 10.1016/S0898-6568(98)00015-1View ArticlePubMedGoogle Scholar
- Mattia E, Carruba G, Angiolella L, Cassone A: Induction of germ tube formation by N-acetyl-D-glucosamine in Candida albicans: uptake of inducer and germinative response. J Bacteriol. 1982, 152: 555-562.PubMed CentralPubMedGoogle Scholar
- Clinical and Laboratory Standards Institute (formly NCCLS) : Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. M27A, Wayne, PA. 1997Google Scholar
- Wilson RB, Davis D, Mitchell AP: Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. J Bacteriol. 1999, 181: 1868-1874.PubMed CentralPubMedGoogle Scholar
- Kofron M, Demel T, Xanthos J, Lohr J, Sun B, Sive H, Osada S, Wright C, Wylie C, Heasman J: Mesoderm induction in Xenopus is a zygotic event regulated by maternal VegT via TGFbeta growth factors. Development. 1999, 126: 5759-5770.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.